The more I think about this oil thing and the cruise industry issues, the more I think that I could potentially buy a cruise ship really cheap and put enough negative-price oil in it to last the rest of my life, and then just live on it. [Reply]
Originally Posted by Dunerdr:
Ive recently started throwing a few hundo at stuff here and there. Hobby- Not my career, and im not dependant on the money invested to give me a return in any way, you know like a hobby something you put money into for entertainment, or for education, of just for satisfaction of doing it. I have some riding on insego and its been a real roller coaster!
Originally Posted by Rain Man:
The more I think about this oil thing and the cruise industry issues, the more I think that I could potentially buy a cruise ship really cheap and put enough negative-price oil in it to last the rest of my life, and then just live on it.
Up front costs aren't terrible, but R&M are pretty high.
iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™
Originally Posted by :
- Company Expands Involvement in the Manufacturing USA® Network, Joining the National Institute for Innovation in Manufacturing Biopharmaceuticals -
NEW YORK , April 27, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today provided an update on its COVID-19 vaccine manufacturing capacity and announced that it has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (“NIIMBL”), one of 14 institutes in the Manufacturing USA Network.
“If our own proprietary SARS-CoV-2 Virus-Like Particle (“VLP”) program, IBIO-200, results in an approved vaccine, we estimate that we could make about 500 million doses of high-quality product annually at our Texas facility, depending upon the potency we see in the clinic,” said Tom Isett, Co-Chairman & CEO of iBio.
“That scalability links directly to the modular technology behind our FastPharming Manufacturing System, which uses a relative of the tobacco plant as the 'bioreactor' to produce biopharmaceuticals,” continued Mr. Isett. “So, the amount of product generated by a single plant is consistent from research- to commercial-scale, and scale-up is achieved by simply growing thousands more plants within our 130,000 square foot facility. This is real innovation in the manufacture of biopharmaceuticals, thus our significant synergy with the NIIMBL community.”